Scientists have identified a new target in ovarian cancer that is particularly vulnerable to chemotherapy. The discovery will allow researchers to better predict how this cancer will behave, particularly the most common and lethal, high-grade serous ovarian cancer (HGSOC). Ovarian cancer is one of the leading causes of cancer deaths among women.
Tag: Ovarian Cancer
Johns Hopkins Researchers Develop Test That Could Identify Aggressive Ovarian Cancers Early
Researchers at the Johns Hopkins Kimmel Cancer Center and the Department of Gynecology and Obstetrics at the Johns Hopkins University School of Medicine have developed an algorithm to identify high-risk precancerous lesions on the fallopian tubes.
The Foundation for Women’s Cancer to Host Free Patient and Advocates Education Forum in San Diego
The Foundation for Women’s Cancer (FWC) is pleased to host a free Patient and Advocate Education Forum on Friday, March 15, 2024, 10 a.m. – 4:30 p.m. PT, in San Diego, CA, at the San Diego Convention Center. The organization welcomes all gynecologic cancer (cervical, endometrial/uterine, ovarian, vaginal, and vulvar) patients, advocates, family members, and providers.
Common chemotherapy drugs don’t work like doctors thought, with big implications for drug discovery
A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.
Researchers identify ‘switch’ to activate cancer cell death
A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.
Using personalized medicine to target gynecological cancers
In this interview, Dr. Salani, who is also a professor of obstetrics and gynecology in the David Geffen School of Medicine at UCLA, talks about the latest research advances for these cancers and how women can help reduce their risk and help with the early detection of the five main types of gynecologic cancers: cervical, ovarian, uterine, vaginal and vulvar.
Arkansas Author Pens Book Detailing Her Survival From Cancer
Angie Choi, a 2015 graduate of UA Little Rock, has written a book detailing how she survived her battle with ovarian cancer using a combination of conventional and alternative medicine.
Major Ovarian Cancer Discovery; Findings Published in Cell
The Birrer Laboratory at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute helped discover a proteogenomic signature in ovarian cancer that may improve the way the disease is treated around the world. The discovery, which identifies a 64-protein-gene signature that can predict primary treatment resistance in patients with high grade ovarian cancer, was published Aug. 3 in the journal Cell.
MD Anderson Research Highlights for August 2, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Recent developments include a novel biomarker that may predict the aggressiveness of pancreatic cancer precursors, insights into the structure and function of a breast and ovarian cancer susceptibility gene, a new approach to overcoming treatment resistance in ovarian cancer, distinguishing features of young-onset rectal cancer, a biomarker and potential target for metastatic lung cancer, machine learning models to better predict outcomes of patients with mantle cell lymphoma (MCL), and a promising therapy for patients with relapsed/refractory MCL.
CAR-T immune therapy attacks ovarian cancer in mice with a single dose
CAR-T immune therapies could be effective against solid tumors if the right targets are identified, a new study led by University of Illinois Urbana-Champaign researchers suggests. The researchers successfully deployed CAR-T in a mouse model of ovarian cancer, a type of aggressive, solid-tumor cancer that has eluded such therapies until now.
Hairdressers, beauticians, accountants may be at heightened risk of ovarian cancer
Hairdressers, beauticians, and accountants are among certain job roles that may be associated with a heightened risk of ovarian cancer, finds a case-control study published online in the journal Occupational & Environmental Medicine.
Pharmacologist: Cancer drug shortage is delaying lifesaving treatments
This year, an estimated 2 million Americans will be diagnosed with cancer. Now, a New York Institute of Technology pharmacology expert contends that these patients’ realities could grow increasingly harsher, as a monthslong shortage of chemotherapy drugs continues. Low supplies of…
MD Anderson Research Highlights for June 7, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
New subtypes identified in difficult-to-treat ovarian cancer – Potential for discovering new treatments
Every year, more than 40,000 women die of ovarian cancer in Europe. Ovarian cancer is a genetically very heterogeneous disease, which makes it exceptionally difficult to study and treat.
Risks of removing ovaries at benign hysterectomy may outweigh the benefits for women at low risk for ovarian cancer
An emulated target trial of more than 140,000 women in Denmark found that removing the ovaries at benign hysterectomy was associated with increased risk for cardiovascular disease in younger women and cancer in older women at low risk for ovarian cancer. These findings support current recommendations for preserving ovaries in premenopausal patients. The findings are published in Annals of Internal Medicine.
AACR: Penn Medicine Preclinical Study Identifies New Target for Recurrent Ovarian Cancer
Results from a preclinical study from Penn Medicine, presented at the AACR Annual Meeting 2023, verified a new target for drug-resistant ovarian cancer and provided data to support a treatment approach that is already making its way into clinical trials.
MD Anderson Research Highlights for March 29, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
TRIAL’S LONG-TERM FOLLOW-UP DATA SHOWS NO DIFFERENCE IN OVERALL SURVIVAL AMONG OVARIAN CANCER PATIENTS WHO DID AND DID NOT RECEIVE PARP INHIBITOR MAINTENANCE THERAPY
After resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy (MT) and those who did not. Results from the trial were presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute.
GYNECOLOGIC CANCER PATIENTS REPORT TIME-RELATED BURDENS AND FINANCIAL TOXICITIES IMPACT QUALITY OF LIFE
Time-related and financial burdens are detrimental to gynecologic cancer patient and survivor quality of life (QOL), according to two research studies presented yesterday and today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
CLINICAL TRIAL PARTICIPATION ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN OVARIAN CANCER PATIENTS
Clinical trial participation was associated with improved overall survival (OS) compared to standard of care therapy among women with platinum-resistant epithelial ovarian cancer (EOC), according to a research study presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
STUDY FINDS INTRIGUING OUTCOMES IN OVARIAN CANCER PATIENTS TREATED WITH PARP INHIBITORS BEFORE SURGICAL INTERVENTION AND SUBSEQUENT CHEMOTHERAPY
Administering PARP inhibitor (PARPi) olaparib prior to surgical intervention and chemotherapy in ovarian cancer patients – a new approach – is feasible and resulted in favorable surgical options, managed adverse events, and positive health outcomes, according to results from the Neoadjuvant Olaparib Window (NOW) Trial presented today by Shannon Westin, MD et al. at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
Study: Spice May Improve Ovarian Cancer Treatment
New research makes the case for why curcumin could help enhance treatment for ovarian cancer.
The Foundation for Women’s Cancer to Host Patient and Advocates Education Forum at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in Tampa on March 24
The Foundation for Women’s Cancer will host a Patients and Advocates Education Forum and Luncheon on Friday, March 24, 2023 in Tampa, FL during the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer.
MD Anderson Research Highlights for March 8, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Risk of cancer remains high for women over 50 with genetic BRCA1 or BRCA2 mutation
Although genetic mutations in BRCA1 or BRCA2 are associated with a younger onset of breast and ovarian cancer, women with these genetic mutations continue to face a high risk of cancer incidence after age 50, even if they have not been previously diagnosed with cancer.
UC San Diego Health Expert Available to Talk about New Recommendation for Ovarian Cancer Prevention
The Ovarian Cancer Research Alliance is urging some women to remove their fallopian tubes to avoid ovarian cancer, even those at low risk. The research group recommends eligible women to have the removal performed if they are finished having children…
Mayo Clinic researchers link ovarian cancer to bacteria colonization in microbiome
A specific colonization of microbes in the reproductive tract is commonly found in women with ovarian cancer, according to a new study from Mayo Clinic’s Center for Individualized Medicine. The discovery, published in Scientific Reports, strengthens evidence that the bacterial component of the microbiome — a community of microorganisms that also consists of viruses, yeasts and fungi — is an important indicator for early detection, diagnosis and prognosis of ovarian cancer.
MD Anderson Research Highlights for January 11, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
MD Anderson Research Highlights for December 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy side effects, updates to the world’s largest cancer drug discovery knowledgebase, improvements to treatment response by blocking the EGFR pathway, and a novel noninvasive diagnostic test for immunotherapy-related kidney injury.
Machine learning model builds on imaging methods to better detect ovarian lesions
Research from Quing Zhu’s lab yields a novel method to use ultrasound to enhance machine learning’s ability to accurately diagnose – or rule out – ovarian cancer.
Researchers Receive $3.2 Million to Study Efficacy of Mind-body Practices in Improving Pain, Surgical Outcomes
Can mind-body practices such as gentle yoga or self-reflection benefit patients undergoing surgery? It’s a question that researchers at Wake Forest University School of Medicine are examining with the support of a five-year, $3.2 million grant from the National Cancer Institute (NCI).
New Study in JNCCN Presents Evidence for ‘Tough Conversations’ Around Racism in Access to Cancer Care
A study in JNCCN, led by researchers at Duke University School of Medicine, found that Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment for ovarian cancer compared to Non-Hispanic White patients, even after adjusting for healthcare access issues.
Restoring the gut biome after antibiotics could lead to better outcomes for ovarian cancer patients
Antibiotics routinely used in ovarian cancer care indiscriminately kill gut bacteria, leading to faster cancer progression and lower survival rates, according to recent Cleveland Clinic research.
MD Anderson Research Highlights for November 3, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
CANCER RESEARCH INSTITUTE TO HOST ANNUAL VIRTUAL IMMUNOTHERAPY PATIENT SUMMIT ON NOVEMBER 11-12, 2022
Free online event for cancer patients and caregivers featuring immunotherapy experts and patient advocates taking place Nov. 11-12, 2022.
MD Anderson Research Highlights for October 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a combination approach to overcome PARP inhibitor resistance in breast and ovarian cancers, a deeper understanding of STAT3 mutations as drivers of disease progression, insights into the “obesity paradox” in men with advanced melanoma, a prognostic model for rapidly progressing vestibular schwannoma, and a role for cellular trafficking proteins in creating a metastasis-promoting lung cancer microenvironment.
Identifying the Underlying Causes of Ovarian Cancer
Two new discoveries led by Cedars-Sinai Cancer investigators help improve the understanding of what drives the development of ovarian cancer and why some women’s tumors do not respond to therapy.
Machine learning creates opportunity for new personalized therapies
Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors. The study appeared in Nature Metabolism.
JMIR Cancer | The Information Needs of Patients With Ovarian Cancer
JMIR Publications recently published “Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study” in JMIR Cancer, which reported that experts in gynecological cancer care recommend that all patients with invasive or high-grade ovarian cancer (OC) undergo genetic testing. However, even patients who intend to take or have taken genetic tests have many unaddressed information needs regarding genetic testing. Existing genetic counseling falls short of adequately addressing this challenge.
Wistar Scientists Identify Novel Therapeutic Approach to Re-activate Immune Response Against Tumors
Wistar scientists identified that inhibiting therapeutic target KDM5A boosts a person’s immune response to tumors.
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage Cancers
Initial study results show that an experimental drug, called nemvaleukin alfa, when used alone or in combination with another anticancer drug (pembrolizumab) may be effective in treating several types of late-stage cancers in some patients.
MD Anderson Research Highlights for May 4, 2022
Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.
AI Model Trained on Video Images Successfully Predicts Treatment Outcomes in Ovarian Cancer Patients
Artificial intelligence (AI) can predict treatment outcomes in ovarian cancer at the time of pre-surgical assessment with a high degree of accuracy, according to results of a new pilot study.
Yale Cancer Center Study Shows New Strategy to Fight Drug Resistance in HER2-Positive Breast and Ovarian Cancers
New findings by researchers at Yale Cancer Center demonstrate a novel strategy to treat tumor growth in breast and ovarian cancers characterized by HER2 gene amplification, an increase in the number of copies of a gene.
Wistar Scientists Identify New Therapeutic Target in Ovarian Cancer Subtype With Poor Prognosis
PHILADELPHIA — (Sept. 21, 2021) — Mutations in the ARID1A gene are present in more than 50% of ovarian clear cell carcinomas (OCCC), for which effective treatments are lacking. Scientists at The Wistar Institute discovered that loss of ARID1A function…
Roswell Park and University of Chicago Medicine Comprehensive Cancer Centers Awarded Nearly $9M for Ovarian Cancer Research
For years, scientists at Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have devoted themselves to research to better understand ovarian cancer.
Roswell Park and University of Chicago Medicine Comprehensive Cancer Centers Awarded Nearly $9M for Ovarian Cancer Research
Researchers from Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center are combining efforts after together securing a nearly $9 million grant from the National Cancer Institute (NCI) to develop new and better treatments for ovarian cancer.
Women’s Wellness: Types of Gynecologic Cancers and their Warning Signs
September is Gynecologic Cancer Awareness Month. Rutgers Cancer institute of New Jersey Gynecologic Oncology Chief Dr. James Aikins reminds women about the types of gynecologic cancers and their warning signs
Experimental Model of Ovarian Cancer Shows Effect of Healthy Cell Arrangement in Metastasis
A key element to slowing metastasis in ovarian cancer is understanding the mechanisms of how tumor cells invade tissues. In APL Bioengineering, biophysics researchers explain how microscopic defects in how healthy cells line up can alter how easily ovarian cancer cells invade tissue. Using an experimental model, the group found that disruptions in the normal cellular layout, called topological defects, affect the rate of tumor cell invasion.
UT Southwestern Finds Crucial New Molecular Mechanisms And Biomarkers in Ovarian Cancer
DALLAS – July 30, 2021 – UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.